摘要
分析盐酸二甲双胍片联合罗格列酮对非酒精性脂肪肝的疗效及对肝功能与血脂的影响。选取该院2018年10月至2020年6月收治的120例非酒精性脂肪肝患者作为研究对象,按治疗方案不同分为两组,对照组60例,予以盐酸二甲双胍片口服;观察组60例,使用盐酸二甲双胍片+罗格列酮进行治疗。观察并记录两组临床疗效、治疗前、后患者的肝功能指标[丙谷转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBiL)、谷氨酰转移酶(GGT)和碱性磷酸酶(ALP)]、血脂指标[总胆固醇(TC)和甘油三酯(TG)]及不良反应发生率,然后进行统计学分析。观察组临床总有效率为93.33%,明显高于对照组的66.67%,差异有统计意义(P<0.05);两组治疗后血清AST、ALT、TBiL、GGT和ALP水平均显著下降(P<0.05),但观察组指标水平下降幅度明显更大,差异有统计意义(P<0.05);两组治疗后血清TC和TG水平均显著下降(P<0.05),但观察组指标水平下降幅度明显更大,差异有统计意义(P<0.05);观察组不良反应总发生率为11.67%,对照组为8.33%,差异无统计意义(P>0.05)。盐酸二甲双胍片联合罗格列酮治疗非酒精性脂肪肝,能够有效改善患者肝功能和血脂水平,提高临床疗效,兼具安全性和有效性,值得临床予以推广。
To analyze the curative effect of metformin hydrochloride tablets combined with rosiglitazone on non-alcoholic fatty liver and its effect on liver function and blood lipids,a total of 120 patients with non-alcoholic fatty liver disease admitted to the authors hospital from October 2018 to June 2020 were selected as the research subjects.They were divided into two groups according to different treatment plans.The control group was 60 cases and received oral metformin hydrochloride tablets,and the observation group 60 cases,used metformin hydrochloride tablets+rosiglitazone for treatment.Observe and record the clinical efficacy of the two groups and the liver function indexes of the patients before and after treatment,[Gamma-glutamin aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBiL),glutamyl transferase(GGT)and alkaline Phosphatase(ALP)],blood lipid indexes[total cholesterol(TC)and triglycerides(TG)]and the incidence of adverse reactions were then statistically analyzed.The total clinical effective rate of the observation group was 93.33%,which was significantly higher than the 66.67%of the control group,the difference was statistically significant(P<0.05).The serum AST,ALT,TBiL,GGT and ALP levels of the two groups decreased significantly after treatment(P<0.05),but the index level of the observation group decreased significantly,and the difference was statistically significant(P<0.05).Serum TC and TG levels decreased significantly after treatment in the two groups(P<0.05),but the observation group decreased significantly,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 11.67%,and the control group was 8.33%,and the difference was not statistically significant(P>0.05).The combination of metformin hydrochloride tablets and rosiglitazone in the treatment of non-alcoholic fatty liver can effectively improve the liver function and blood lipid levels of patients,improve the clinical efficacy,and is safe and effective,it is worthy of clinical promotion.
作者
李煜
尚晓琳
LI Yu;SHANG Xiao-lin(Department of Gastroenterology,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032,China;Department of Gastroenterology,Changwu Hospital of Traditional Chinese Medicine Xianyang City,Shaanxi Province,Changwu 713600,China)
出处
《药物生物技术》
CAS
2022年第1期63-66,共4页
Pharmaceutical Biotechnology
关键词
非酒精性脂肪肝
盐酸二甲双胍
罗格列酮
肝功能
血脂
Nnon-alcoholic fatty liver
Metformin hydrochloride
Rosiglitazone
Liver function
Blood lipids
